Assessment of cardiac safety during fingolimod treatment initiation in a real-world relapsing multiple sclerosis population: a phase 3b, open-label study-Reference-Cited by-同舟云学术

Assessment of cardiac safety during fingolimod treatment initiation in a real-world relapsing multiple sclerosis population: a phase 3b, open-label study

Published:2013-11-13 Issue:2 Volume:261 Page:267-276
ISSN:0340-5354
Container-title:Journal of Neurology
language:en
Short-container-title:J Neurol

Author:

Gold Ralf, ,Comi Giancarlo,Palace Jacqueline,Siever Arno,Gottschalk Rebecca,Bijarnia Mahendra,von Rosenstiel Philipp,Tomic Davorka,Kappos Ludwig

Publisher

Springer Science and Business Media LLC

Subject

Neurology (clinical),Neurology

Link

http://link.springer.com/article/10.1007/s00415-013-7115-8/fulltext.html

Reference18 articles.

1. Brinkmann V, Davis MD, Heise CE, Albert R, Cottens S, Hof R, Bruns C, Prieschl E, Baumruker T, Hiestand P, Foster CA, Zollinger M, Lynch KR (2002) The immune modulator FTY720 targets sphingosine 1-phosphate receptors. J Biol Chem 277(24):21453–21457

2. European Medicines Agency (2011) Annex I. Summary of product characteristics. Gilenya (fingolimod). http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002202/WC500104528.pdf . Accessed 8 October 2012

3. European Medicines Agency (2012) Revised summary of product characteristics. Gilenya (fingolimod). http://www.ema.europa.eu/docs/en_GB/document_library/Other/2012/04/WC500125687.pdf . Accessed 8 October 2012

4. US Food and Drug Administration (2010) Gilenya prescribing information. http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/022527s002lbl.pdf . Accessed 8 October 2012

5. US Food and Drug Administration (2012) Gilenya (fingolimod): revised US prescribing information. http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/022527s008lbl.pdf . Accessed 8 October 2012

Cited by 116 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Safety of fingolimod in patients with relapsing remitting multiple sclerosis: A descriptive analysis of data from the EudraVigilance database;Journal of the Neurological Sciences;2024-08

2. Potential adverse events associated with sphingosine-1-phosphate (S1P) receptor modulators in patients with multiple sclerosis: an analysis of the FDA adverse event reporting system (FAERS) database;Frontiers in Pharmacology;2024-05-23

3. Pre-existing parasympathetic dominance seems to account for heart rate slowingafter six months of Fingolimod-treatment in patients with multiple sclerosis;2024-03-12

4. Update and Application of a Deep Learning Model for the Prediction of Interactions between Drugs Used by Patients with Multiple Sclerosis;Pharmaceutics;2023-12-19

5. Sphingosine-1-phosphate receptor modulators in the treatment of early phase multiple sclerosis;Neurologie pro praxi;2023-10-30